ELEGI Colt Laboratory, Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh
Validity of physical activity monitors during daily life in patients with COPD
- Published on Nov. 1, 2013
Background: Symptoms during physical activity and physical inactivity are hallmarks of chronic obstructive pulmonary disease (COPD). Our aim was to evaluate the validity and usability of six activity monitors in patients with COPD against the doubly labelled water (DLW) indirect calorimetry method.
Methods: 80 COPD patients (mean±SD age 68±6 years and forced expiratory volume in 1 s 57±19% predicted) recruited in four centres each wore simultaneously three or four out of six commercially available monitors validated in chronic conditions for 14 consecutive days. A priori validity criteria were defined. These included the ability to explain total energy expenditure (TEE) variance through multiple regression analysis, using TEE as the dependent variable with total body water (TBW) plus several physical activity monitor outputs as independent variables; and correlation with activity energy expenditure (AEE) measured by DLW.
Results: The Actigraph GT3X (Actigraph LLC, Pensacola, FL, USA), and DynaPort MoveMonitor (McRoberts BV, The Hague, the Netherlands) best explained the majority of the TEE variance not explained by TBW (53% and 70%, respectively) and showed the most significant correlations with AEE (r=0.71, p<0.001 and r=0.70, p<0.0001, respectively).
Conclusions: The results of this study should guide users in choosing valid activity monitors for research or for clinical use in patients with chronic diseases such as COPD.
- Roberto A. Rabinovich 1, 8
- Zafeiris Louvaris 2, 8
- Yogini Raste 3
- Daniel Langer 4
- Hans Van Remoortel 4
- Santiago Giavedoni 1
- Chris Burtin 4
- Eloisa M.G. Regueiro 5
- Ioannis Vogiatzis 2
- Nicholas S. Hopkinson 3
- Michael I. Polkey 3
- Frederick J. Wilson 6
- William MacNee 1
- Klaas R. Westerterp 7
- Thierry Troosters 4
- on behalf of the PROactive consortium
Dept of Critical Care Medicine, Pulmonary Rehabilitation Centre, Evangelismos Hospital, M. Simou and G.P. Livanos Laboratories, National and Kapodistrian University of Athens, Thorax Foundation, Athens, Greece
NIHR Respiratory Biomedical Research Unit of the Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College London, London
Dept of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
Laboratory of Respiratory Physiotherapy, Universidade Federal de São Carlos (UFSCar), São Carlos, Brazil
Precision Medicine, Pfizer Worldwide Research and Development, Sandwich, UK
Dept of Human Biology, Maastricht University, Maastricht, The Netherlands
Both authors contributed equally
European Respiratory Journal